Navigating the Data: Patient Eligibility for Novel Oral Therapies in EBC

Did you know that EBC patients may stop treatment early, due to safety or tolerability, increasing risk of recurrence, hence the need for newer options?

Credit available for this activity expires: 10/30/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/navigating-data-patient-eligibility-novel-oral-therapies-ebc-2026a10014e1?ecd=bdc_podcast_libsyn_mscpedu